
University of Pennsylvania
3451 Walnut St, Philadelphia, Pennsylvania, 19104, United States
Overview
Ivy League university offering diverse liberal arts and sciences programs.
Founded
1740
Deals ยท 12mo
0
Links
Stage focus
Geographic focus
Sector focus
Investment portfolio
| NAME | DATE | SIZE | |
|---|---|---|---|
Dispatch Bio | Jul 2025Participated | $216 MSeries A | |
Vittoria Biotherapeutics | Nov 2024Participated | $10 MOther Equity | |
Elemind Technologies | Feb 2024Participated | $12 MSeed | |
Interius BioTherapeutics | May 2021Participated | $76 MSeries A | |
Tmunity Therapeutics | Oct 2019Participated | $75 MSeries B | |
Linnaeus Therapeutics | Sep 2019Participated | $12 MSeries B | |
Node | Jul 2019Participated | $16 MOther Equity | |
Tmunity Therapeutics | Jan 2018Participated | $100 MSeries A | |
Dispatch Bio | Jul 2025Participated | $216 MSeries A | |
Vittoria Biotherapeutics | Nov 2024Participated | $10 MOther Equity | |
Elemind Technologies | Feb 2024Participated | $12 MSeed | |
Interius BioTherapeutics | May 2021Participated | $76 MSeries A | |
Tmunity Therapeutics | Oct 2019Participated | $75 MSeries B | |
Linnaeus Therapeutics | Sep 2019Participated | $12 MSeries B | |
Node | Jul 2019Participated | $16 MOther Equity | |
Tmunity Therapeutics | Jan 2018Participated | $100 MSeries A |
Insights
Time horizon
View by
Deal Distribution
| Round type | Led deals | Participated deals |
|---|---|---|
| Seed | 0 | 1 |
| Series A | 0 | 3 |
| Series B | 0 | 2 |
| Other Equity | 0 | 2 |
Monthly Deal Activity
| Month | Deals |
|---|---|
| Jan '18 | 1 |
| Feb '18 | 0 |
| Mar '18 | 0 |
| Apr '18 | 0 |
| May '18 | 0 |
| Jun '18 | 0 |
| Jul '18 | 0 |
| Aug '18 | 0 |
| Sep '18 | 0 |
| Oct '18 | 0 |
| Nov '18 | 0 |
| Dec '18 | 0 |
| Jan '19 | 0 |
| Feb '19 | 0 |
| Mar '19 | 0 |
| Apr '19 | 0 |
| May '19 | 0 |
| Jun '19 | 0 |
| Jul '19 | 1 |
| Aug '19 | 0 |
| Sep '19 | 1 |
| Oct '19 | 1 |
| Nov '19 | 0 |
| Dec '19 | 0 |
| Jan '20 | 0 |
| Feb '20 | 0 |
| Mar '20 | 0 |
| Apr '20 | 0 |
| May '20 | 0 |
| Jun '20 | 0 |
| Jul '20 | 0 |
| Aug '20 | 0 |
| Sep '20 | 0 |
| Oct '20 | 0 |
| Nov '20 | 0 |
| Dec '20 | 0 |
| Jan '21 | 0 |
| Feb '21 | 0 |
| Mar '21 | 0 |
| Apr '21 | 0 |
| May '21 | 1 |
| Jun '21 | 0 |
| Jul '21 | 0 |
| Aug '21 | 0 |
| Sep '21 | 0 |
| Oct '21 | 0 |
| Nov '21 | 0 |
| Dec '21 | 0 |
| Jan '22 | 0 |
| Feb '22 | 0 |
| Mar '22 | 0 |
| Apr '22 | 0 |
| May '22 | 0 |
| Jun '22 | 0 |
| Jul '22 | 0 |
| Aug '22 | 0 |
| Sep '22 | 0 |
| Oct '22 | 0 |
| Nov '22 | 0 |
| Dec '22 | 0 |
| Jan '23 | 0 |
| Feb '23 | 0 |
| Mar '23 | 0 |
| Apr '23 | 0 |
| May '23 | 0 |
| Jun '23 | 0 |
| Jul '23 | 0 |
| Aug '23 | 0 |
| Sep '23 | 0 |
| Oct '23 | 0 |
| Nov '23 | 0 |
| Dec '23 | 0 |
| Jan '24 | 0 |
| Feb '24 | 1 |
| Mar '24 | 0 |
| Apr '24 | 0 |
| May '24 | 0 |
| Jun '24 | 0 |
| Jul '24 | 0 |
| Aug '24 | 0 |
| Sep '24 | 0 |
| Oct '24 | 0 |
| Nov '24 | 1 |
| Dec '24 | 0 |
| Jan '25 | 0 |
| Feb '25 | 0 |
| Mar '25 | 0 |
| Apr '25 | 0 |
| May '25 | 0 |
| Jun '25 | 0 |
| Jul '25 | 1 |
| Aug '25 | 0 |
| Sep '25 | 0 |
| Oct '25 | 0 |
| Nov '25 | 0 |
| Dec '25 | 0 |
| Jan '26 | 0 |
| Feb '26 | 0 |
| Mar '26 | 0 |
| Apr '26 | 0 |
| May '26 | 0 |
| Jun '26 | 0 |
| Jul '26 | 0 |
| Aug '26 | 0 |
| Sep '26 | 0 |
| Oct '26 | 0 |
Sector Breakdown
A deal can appear in multiple sectors, so sector totals may overlap. Capital represents disclosed total round sizes, not fund cheque sizes.
| Sector | Deals |
|---|---|
| Health & Life Sciences | 7 |
| Manufacturing | 2 |
| Space & Frontier Tech | 2 |
| Hardware & Robotics | 1 |
| Enterprise Software | 1 |
| AI & Machine Learning | 1 |
| Data, Analytics & IT | 1 |
Deal Size Distribution
Undisclosed round sizes are excluded. Capital represents total round sizes, not fund cheque sizes.
| Round size band (USD) | Deals |
|---|---|
| <$5M | 0 |
| $5M-$10M | 0 |
| $10M-$25M | 4 |
| $25M-$50M | 0 |
| $50M-$100M | 2 |
| $100M-$250M | 2 |
| $250M-$500M | 0 |
| $500M-$1B | 0 |
| $1B+ | 0 |
Deals By Geography
Top 1 of 1 regions; European countries are grouped as Europe.
| Region | Deals |
|---|---|
| United States | 8 |
Co-Investors
Bubble size = shared deals
Click a bubble to open that fund in a new tab.
Shows up to 20 co-investors ranked by shared deals. Deals may be shared with multiple funds, so rows overlap. Capital is total round size, not fund cheque size.
| Co-investor | Shared deals |
|---|---|
| Agent Capital | 2 |
| Be The Match BioTherapies | 2 |
| BrightEdge | 2 |
| Gilead Sciences | 2 |
| Parker Institute for Cancer Immunotherapy | 2 |
| Tellus BioVentures | 2 |
| Alexandria Venture Investments | 1 |
| American Cancer Society | 1 |
| Andreessen Horowitz | 1 |
| ARCH Venture Partners | 1 |
| Avalon Ventures | 1 |
| Bain Capital Life Sciences | 1 |
| Bristol Myers Squibb | 1 |
| Canaan Partners | 1 |
| Cormorant Asset Management | 1 |
| Dreamers VC | 1 |
| Embark Ventures | 1 |
| Fairmount | 1 |
| GingerBread Capital | 1 |
| Global BioAccess Fund | 1 |
Investment Strategy
| Category | Deals (count) | Share (%) |
|---|---|---|
| Led | 0 | 0% |
| Participating | 8 | 100% |
| Category | Deals (count) | Share (%) |
|---|---|---|
| Single-lead | 0 | 0% |
| Co-led | 0 | 0% |
Lead dynamics requires at least one led deal in this range
Team
University Professor of Psychiatry
Sr. Director, Translational Research & Portfolio Development
Founding Father, Chairman, President and CEO
Director, Clinical Cell and Vaccine Production Facility
Assistant Professor of Clinical Neurology
Adjunct Professor of Landscape Architecture
Instructor, Annenberg School For Communication
Olga and Alberico Pompa Professor of Engineering and Applied Science
Director, T Cell Engineering Lab (TCEL) & Adjunct Associate Professor